Entity

Time filter

Source Type

Raleigh, NC, United States

Salix Pharmaceuticals, Inc. is a specialist American pharmaceutical company. It develops drugs and medical devices that prevent and treat various gastrointestinal disorders. It is listed in the Russell 2000 index. This company is listed as having the most revenue per employee by Bizjournals.com. Wikipedia.


Background:Pazopanib, an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit, is approved in locally advanced/metastatic renal cell carcinoma (RCC).Methods:Data from trials in advanced solid tumours and advanced/metastatic RCC were used to explore the relationships between plasma pazopanib concentrations and biomarker changes, safety, and efficacy. Initially, the relationships between pharmacokinetic parameters and increased blood pressure were investigated, followed by analysis of steady-state trough concentration (Cτ) and sVEGFR2, safety, progression-free survival (PFS), response rate, and tumour shrinkage. Efficacy/safety end points were compared at Cτ decile boundaries.Results:Strong correlation between increased blood pressure and Cτ was observed (r2=0.91), whereas weak correlation was observed between Cτ and decline from baseline in sVEGFR2 (r2=0.27). Cτ threshold of >20.5 μg ml-1 was associated with improved efficacy (PFS, P<0.004; tumour shrinkage, P<0.001), but there was no appreciable benefit in absolute PFS or tumour shrinkage from Cτ >20.5 μg ml-1. However, the association of Cτ with certain adverse events, particularly hand–foot syndrome, was continuous over the entire Cτ range.Conclusions:The threshold concentration for efficacy overlaps with concentrations at which toxicity occurs, although some toxicities increase over the entire Cτ range. Monitoring Cτ may optimise systemic exposure to improve clinical benefit and decrease the risk of certain adverse events.British Journal of Cancer advance online publication, 28 October 2014; doi:10.1038/bjc.2014.503 www.bjcancer.com. © 2014 Cancer Research UK


Patent
Salix Pharmaceuticals and Alfa Wassermann S.P.A. | Date: 2015-05-08

25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided.


Patent
Salix Pharmaceuticals | Date: 2015-02-24

Methods of reducing weight in a subject are provided, wherein the methods comprise administering a composition comprising an effective amount of rifaximin to a subject in need of treatment for weight loss. In some embodiments, the subject is considered obese (BMI>30).


Methods of increasing the long-term survival odds for a subject suffering from hepatic encephalopathy are provided, wherein the methods include administering a composition comprising rifaximin to the subject. Methods of reducing the frequency of hospitalization visits by a subject suffering from HE are also provided, wherein the methods include administering a composition comprising rifaximin to the subject.


Patent
Salix Pharmaceuticals | Date: 2015-02-24

Methods of administering a composition comprising rifaximin to a subject in need thereof are provided, wherein the methods do not increase development of rifampicin resistance to a

Discover hidden collaborations